Kestra Medical insider files notice to sell stock

Vaseem Mahboob filed a notice of intent to sell common stock of Kestra Medical Technologies, Ltd. under Rule 144, with sales to be executed through Merrill Lynch on or after July 31, 2026 on the NASDAQ market.

Rhea-AI Filing Summary

Vaseem Mahboob filed a notice of intent to sell common stock of Kestra Medical Technologies, Ltd. under Rule 144, with sales to be executed through Merrill Lynch on or after July 31, 2026 on the NASDAQ market.

The common shares were originally acquired through the vesting of performance share unit awards on July 17, 2026 as part of the issuer’s equity compensation plan. The filing also notes a prior sale during the last three months of 3,980 common shares for $90,560.62. The issuer reports 58,602,497 common shares outstanding in connection with this notice.

Key Figures

Aggregate market value noted: 199,344.62 Shares outstanding: 58,602,497 shares Prior 3-month sale shares: 3,980 shares +3 more

6 metrics

Aggregate market value noted 199,344.62 Referenced with the common stock in the Rule 144 notice

Shares outstanding 58,602,497 shares Common shares outstanding referenced in connection with the Rule 144 filing

Prior 3-month sale shares 3,980 shares Common stock sold on July 30, 2026 during the past three months

Prior 3-month sale value $90,560.62 Total value of 3,980 shares sold on July 30, 2026

Planned sale date 07/31/2026 Approximate date of proposed Rule 144 sales

PSU vesting date 07/17/2026 Date performance share unit awards vested and shares were acquired

Key Terms

Rule 144, performance share unit awards, equity compensation plan

3 terms

Rule 144 regulatory

"144: Securities Information Common Stock"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

performance share unit awards financial

"Vesting of performance share unit awards"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kestra Medical Technologies (KMTS) disclose in this Form 144?

The filing shows Vaseem Mahboob submitted a Rule 144 notice to potentially sell Kestra Medical common stock through Merrill Lynch on or after July 31, 2026, with the shares listed for trading on NASDAQ.

How many Kestra Medical (KMTS) shares are noted as outstanding in this filing?

The Form 144 references 58,602,497 Kestra Medical Technologies common shares outstanding. This figure provides context for the issuer’s overall equity base relative to the insider’s potential Rule 144 sales activity.

How were the Kestra Medical (KMTS) shares to be sold originally acquired?

The shares were acquired through the vesting of performance share unit awards on July 17, 2026, which were granted as part of the issuer’s equity compensation plan to the reporting person.

What prior Kestra Medical (KMTS) stock sale is reported for the last three months?

The filing reports that 3,980 common shares were sold on July 30, 2026 for a total of $90,560.62. This disclosure satisfies Rule 144 requirements on securities sold during the preceding three months.

Which broker and exchange are involved in this Kestra Medical (KMTS) Form 144?

The planned Rule 144 sales are to be executed through Merrill Lynch, with Kestra Medical common stock listed for trading on the NASDAQ exchange according to the filing details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:32 PM Accepted by SEC EDGAR 07/31/2026 - 04:31 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001655157
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Mahboob Vaseem
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	8817	199344.62	58602497	07/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Vesting of performance share unit awards	KESTRA MEDICAL TECHNOLOGIES, LTD.			8817	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Vaseem Mahboob 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Stock	07/30/2026	3980	90560.62

144: Remarks and Signature

Remarks
Date of Notice	07/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Vaseem Mahboob
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)